It is expected that fewer patients will be taking Tysabri, used to treat multiple sclerosis, as two more patients have been diagnosed with a potentially fatal brain disease. Financial analysts predict that the drug will have only about 75,000 users by 2013, which is below Biogen Idec Inc.'s goal of 100,000.
Trending:
Lower sales of Tysabri predicted